Kornimate/medical-research-clean huggingface dataset:
dual wavelength oct

Conditions: AMD; Diabetic Retinopathy; Retinal Degeneration; Retinal Dystrophies

Summary: the purpose of this research is the evaluation of a combined coaxial optical coherence tomography (oct) system to image retina/choroid and to evaluate if post processing of the data can give us insights into property of the tissue imaged.

histology studies have shown that many disorders of the retina and choroid such as age-related macular degeneration is associated with a build up abnormal deposits, in the retina or subretinal space. being able to detect subtle changes in retina and choroidal structure is crucial for better understanding and monitoring of this potentially blinding condition. this study aims to commercially available spectralis® oct-system with a central wavelength of 880nm explore the ability of a confocal scanning laser ophthalmoscope (cslo) for oct imaging utilising a modified by the addition of a longer wavelength oct (1075nm , a wavelength deployed on other commercially available oct scanners). other commercially available oct scanners used longer wavelengths to allow deeper penetration and enhanced visualisation of subretinal tissue but less inner retinal detail. combing both wavelengths could have the advantage of allowing optimum viualisation of inner and subretinal structures. the ability of the systems to acquire repeatable and good quality images of retinal and choroidal structural detail at matching location and compare the results from the two instruments will be evaluated. in addition processing of the images reflectivity with two different wavelength should give us insight into the nature of any abnormal material.

Eligibility criteria:
inclusion criteria: * age\>18 * ability to consent * abnormal reflectivity detected in at least one eye in the retina or choroid on oct testing undertaken as part of routine * clinical care exclusion criteria: * media opacities on conventional oct testing taken on the day of the study visit, that prevents adequate visualisation of * the retina and/or choroidal substructures in the opinion of the investigator * inability to undertake to undertake two additional oct scans on each eye in addition to their conventional oct.
dissecting the cellular and molecular atlas of rheumatoid arthritis in sustained remission to identify pathways maintaining remission and triggering flares

Conditions: Rheumatoid Arthritis

Summary: the flare-ra study will have the following research objectives: a) to establish the cellular and molecular atlas of remission ra achieved with different therapeutics aimed to identify (i) cell clusters/pathways driving disease flare or maintaining remission and (ii) provide an evidence base for developing ml tools for predicting flares. b) to test the performance of a ml-derived algorithm on longitudinal remission ra cohort in a biopsy-driven study. c) to dissect the cellular and molecular mechanisms of remission maintenance and joint flares.


Eligibility criteria:
inclusion criteria: * rheumatoid arthritis classified based on the 2010 eular/acr classification criteria * stable treatment with cdmards and/or bdmards (≥12 months) * stable remission status (at least das28-crp\<2.6) (≥6 months) * no concomitant steroid treatment (≥6 months) * absence of power-doppler signal at ultrasound assessment (wrist, mcp, pip, knee, ankle and ii-v mtp bilaterally) in 3 evaluations 3 months apart. exclusion criteria: * das28-crp≥2.6 * presence of power-doppler signal ≥1 at ultrasound assessment (wrist, mcp, pip, knee, ankle and ii-v mtp bilaterally) * other chronic inflammatory disease
a phase i study of intrathecal rituximab in patients with lymphomatous meningitis

Conditions: Lymphoma, B Cell

Summary: the purpose of this study is to define the safety profile of rituximab given intrathecally in lymphomatous meningitis related to cd20+ non-hodgkin's lymphomas.


Eligibility criteria:
inclusion criteria: 1. lymphomatous meningitis documented by positive csf cytology in either newly diagnosed, relapsed or refractory primary cns or systemic nhl 2. pathologically diagnosed cd20-positive nhl 3. age ≥ 18 years 4. ecog performance status 0 - 2 (see appendix a) 5. life expectancy of at least 1 month 6. informed consent must be given according to national/local regulations before enrollment (see appendix b) 7. patients may have had prior cns irradiation, intrathecal methotrexate, cytarabine or thiotepa for treatment of lymphomatous meningitis but these treatments must have completed at least two weeks before the study enrollment and the patients must have recovered from any reversible toxicity caused by prior treatments 8. concurrent systemic chemotherapy is allowed with the exception of high-dose methotrexate (\>500 mg/m2/day), high-dose cytarabine (\>2 g/m2/day), high-dose thiotepa (\>300 mg/m2/day) or investigational agents 9. no concurrent intrathecal chemotherapy other than rituximab 10. no severe impairment of bone marrow function (anc \>1.5x109/l, plt \>50x109/l), unless due to proven lymphoma involvement 11. no major impairment of renal function (serum creatinine \< 1,5 x upper normal) or liver function (asat/alat \< 2,5 upper normal, total bilirubin \<2,5x upper normal), unless due to proven lymphoma involvement 12. no evidence of active opportunistic infections 13. no hiv infection 14. no pregnant or lactating status 15. appropriate contraceptive method in women of childbearing potential or men 16. absence of any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule; those conditions should be discussed with the patient before registration in the trial 17. absence of a obstructive hydrocephalus or compartimentalization of csf flow.
glecaprevir/pibrentasvir fixed-dose combination treatment for acute hepatitis c virus infection

Conditions: Hepatitis C Infection; HIV Infection

Summary: the purpose of this study was to assess the efficacy of a fixed dose combination (fdc) of glecaprevir/pibrentasvir (g/p) given for 4 weeks for treatment of acute hepatitis c (hcv), with or without hiv-1 coinfection.

the study was conducted in two steps. in step 1, participants received four weeks of treatment with g/p for acute hcv infection and were then followed 24 weeks post treatment. participants with hcv recurrence (reinfection, suspected relapse or undefined post-treatment viremia) or hcv virologic failure before or at the step 1 week 16 entered step 2 and were offered hcv re-treatment. the remaining participants were followed in step 1 for a total of 28 weeks. the study primary and secondary outcome measures pertain to step 1. in step 2, participants were re-treated for up to 16 weeks (g/p or alternate regimen through standard of care), and were followed for 24 weeks post treatment. this post-treatment follow-up included a visit for the determination of hcv sustained virologic response (svr12) after re-treatment. all summaries of data captured from step 2 are pooled across hcv re-treatment regimens, as specified in the statistical analysis plan. in step 1, study visits were scheduled at study entry, weeks 1 and 2 (on-treatment), week 4 (treatment discontinuation), and weeks 8, 12, 16 and 28 (post-treatment follow-up). in step 2, participants had study visits during the re-treatment period, where the number of visits depended on the re-treatment regimen, and at weeks 12 and 24 post treatment. study visits included physical examinations, clinical assessments, blood and urine collection, questionnaires, and hcv re-infection prevention counseling.

Eligibility criteria:
inclusion criteria * acute hcv infection (or reinfection) within 24 weeks prior to entry * detectable hcv rna at the screening visit exclusion criteria * any hcv treatment during the current acute hcv infection episode * known preexisting cirrhosis * acute hiv-1 infection * presence of active or acute aids-defining opportunistic infections, active serious infection (other than hiv-1 or hcv), active hepatitis b virus (hbv) or active hepatitis a virus (hav) * chronic use of systemically administered immunosuppressive agents * history of solid organ transplantation * history of conditions that could interfere with the absorption of the study drug * concurrent use of prohibited medications * known hypersensitivity to glecaprevir or pibrentasvir, the metabolites, or parts of the formulation * females who are pregnant or breastfeeding * males with pregnant female partner

Keywords: acute hepatitis c infection glecaprevir pibrentasvir 4 weeks direct-acting antivirals
effect of diet orange soda on urinary lithogenicity

Conditions: Kidney Stones; Nephrolithiasis; Urolithiasis

Summary: beverages containing citrate may be useful in increasing urine citrate content and urine ph. such changes in urine chemistry could help prevent kidney stones. diet orange soda has more citrate than other similar beverages. the investigators are interested in whether diet soda will improve urine chemistry in the appropriate manner.

the effect of orange soda compared with water in changing 24 hour urine citrate excretion in mg/day will be determined.

Eligibility criteria:
inclusion criteria: * 18-65 years old * able to sign consent * ability to reliably urinate into a vessel and measure urine volume exclusion criteria: * prior history of nephrolithiasis * a known history of metabolic bone disease * hyperthyroidism * hyperparathyroidism or chronic kidney disease * current use of diuretics * current use of potassium citrate or other oral alkali supplementation and * use of calcium supplementation that could not be stopped

Keywords: kidney stones calcium citrate
pharmacokinetics, metabolism, efficacy, and safety study of two testosterone matrix transdermal systems

Conditions: Hypogonadism

Summary: watson's testosterone transdermal system delivers male sex hormone through skin for the treatment of men with sex hormone insufficiency.

the present study is designed to characterize efficacy and safety of testosterone from the watson's testosterone matrix transdermal system (tmts).

Eligibility criteria:
inclusion criteria: * male, 18 - 65 years of age; * documented testosterone deficiency; * bmi 18 to 33. exclusion criteria: * evidence of prostate cancer and benign prostate hyperplasia; * taking medications that interfere testosterone metabolism; * history of alcohol or drug substance abuse; * abnormal ecg; * allergic to transdermal products; * skin condition that interfere transdermal system application and assessment

Keywords: hypogonadism, testosterone, transdermal system
women's post traumatic stress disorder (ptsd) research study

Conditions: Posttraumatic Stress Disorder

Summary: the purpose of this study is to examine the relationship between trauma and startle. the investigators are also looking at the effect of menstrual phase on this relationship.

the investigators are trying to understand if there is a relationship between the experience of traumatic events such as those experienced by people with post traumatic stress disorder and reactivity to startling noises or mild threats. so, the investigators are looking at startle reflex, heart rate, and stress hormone responses to short noises and small shocks in people exposed to trauma and who either do or do not have ptsd. additionally, the investigators will be looking at how the menstrual cycle impacts these processes. the investigators know that women have twice the risk for developing ptsd and some research suggests that stress hormones change during the menstrual cycle and may have an effect on risk.

Eligibility criteria:
inclusion criteria: * women, ages 18-55 years old who have a regular menstrual cycle and who can come in to participate in the afternoon exclusion criteria: * long-term medications, oral or steroid contraceptives, irregular menstrual cycle

Keywords: stress stress disorders, post-traumatic stress disorders, traumatic
novel device for screening patients with symptoms of osa

Conditions: Sleep Apnea Syndromes

Summary: an innovative ring type oxymetry will be wore by patient undergoing sleep study to validate it's accuracy and usefulness as a screening device for patients with symptoms of osa


Eligibility criteria:
inclusion criteria: * patients above 18 years old and below 70 years old, both men and women exclusion criteria: * patients requiring oxygen therapy or noninvasive ventilation; * patients with a diagnosis of chronic obstructive pulmonary disease, chronic heart failure, neuromuscular disease, insomnia, clinical symptoms of parasomnia, periodic limb movement, or narcolepsy. * patients on medication known to interfere with heart rate, such as beta-blockers, digoxin or calcium receptor antagonists.
maternal oxygen administration for fetal distress

Conditions: Oxygen Inhalation Therapy; Second Stage of Labour; Fetal Distress

Summary: supplementary oxygen is routinely administered to patients, even those with adequate oxygen saturations, in the belief that it increases oxygen delivery. however, oxygen delivery depends not just on arterial oxygen content but also on perfusion. maternal oxygen administration has been used in an attempt to lessen fetal distress by increasing the available oxygen from the mother. however, the effect of supplemental maternal oxygen therapy on fetal acid base status has been debated for more than seven decades. hypothesis: prophylactic maternal low flow nasal oxygen administration during the second stage of labor can relieve fetal distress.

a report from the cochran library (cochrane database syst rev. 2012 dec 12;12:cd000136.): too little evidence to show whether oxygen administration to the woman during labour is beneficial to the baby. some babies show signs of distress, such as unusual heart rates or the passing of a bowel motion (meconium) during their mother's labour. this may be caused by a lack of oxygen passing from the woman to the baby through the placenta. sometimes, women may be encouraged to breathe extra oxygen through a facemask (oxygen administration) to increase the oxygen available to the unborn baby. a review of two trials found too little evidence to show whether oxygen administration to the woman during the second stage of labour is beneficial to the baby. no trials of oxygen administration when the baby is showing signs of distress were found. further research is needed.

Eligibility criteria:
inclusion criteria: * at term * singleton * primigraida * cephalic presentation * spontaneous or induced labor * normal labor * normal fhr tracings in the first stage * at the onset of second stage exclusion criteria: * respiratory disease * cardiovascular disease * diabetes mellitus or insulin-treated gestational diabetes mellitus * hypertension or preeclampsia * oligohydramnios * fetal growth restriction * placental abruption * anemia * disorders in oxygen saturations * received oxygen therapy in the first stage
unmet needs, barriers and facilitators to vision services for children and adolescents with special vision care needs: a mixed-model design study

Conditions: Vision Disorders

Summary: children and adolescents with special needs, compared to those with general development, have a much higher incidence of visual impairments (10.5% vs. 0.16%). this project will focus on "children and adolescents with special visual care needs", comprehensively exploring their unmet needs in ophthalmology and visual care, as well as the obstacles and facilitators they may encounter in the process of seeking ophthalmic services. the purposes of this study will investigate the current needs of children and adolescents with special visual care needs in ophthalmology and visual medical services, and the obstacles and potential facilitators encountered by children and adolescents with special visual care needs in the process of obtaining ophthalmology and visual medical services.

the research will center on children and adolescents with special visual needs and explore the research questions from various stakeholders' perspectives, including parents, special education teachers and experts, healthcare professionals, workers from related ngos and government units. a mixed-methods research approach will be used to gather both quantitative and qualitative data. after data analysis, a comparison and interpretation between the two results will be conducted to obtain the final research outcomes. 1. quantitative research: two-part questionnaire. the first part collects background information, and the second part is a "needs and difficulties survey", framed by levesque et al.'s conceptual framework of access to healthcare. 2. qualitative research: the first part consists of semi-structured in-depth interviews, and the second part uses the focus group method. both parts will use a common interview guideline and the international classification of functioning, disability and health, child \& youth version (icf-cy) as the theoretical framework.

Eligibility criteria:
inclusion criteria: 1. able to read, understand, and fill out questionnaires in chinese 2. able to conduct interviews in chinese exclusion criteria: 1. the special needs children or adolescents they have taught do not have specific visual needs, hence they cannot provide relevant information.
the influence of an intervention program on altering health behavioral patterns among idf's staff

Conditions: Physical Fitness Habits; Balanced Nutrition; Weight Reduction; Smoking Cessation; Reduction of Stress

Summary: the goal of this study is to determine the effectiveness of a general intervention that includes encouragement of physical activity and healthy living habits of officers and permanent staff in the idf


Eligibility criteria:
inclusion criteria: * idf's staff member * age \>26 * one or more risk factor exclusion criteria: * cardio vascular condition * respiratory disease * other healthy conditions according to the physician's decision
seoul national university hospital gangnam-real time optical diagnosis program 2: gangnam-readi2

Conditions: Colon Polyp

Summary: accurate optical diagnosis of colorectal polyps could allow a "resect and discard" strategy based on the results of the optical biopsy. even though intensive training for optical diagnosis, there is still wide variability in individual endoscopists to meet the pivi thresholds. the investigators with experience of prior optical diagnosis training perform new education and drill to apply proper high confidence according to their decision time. after the education program, the investigators prospectively evaluate real-time optical biopsy analysis of polyps in 8 academic gastroenterologists.

this study is an extension of the gangnam-readi program (nct02516748) in seoul national university hospital healthcare system gangnam center. this study is composed of two periods. first, an education program on predicting polyp histology and real-time optical diagnosis will be performed by 8 endoscopists from february to march 2020. in the second period from april 2020 till october 2020(total 6 months), real-time optical diagnosis with time drill for diminutive and small colorectal polyps will be activated. endoscopists will have 3 seconds rule to make high confidence diagnosis and have feedbacks on their accuracy of optical diagnosis for polyps per 3 months. the performance will be evaluated by comparing the optically predicted diagnosis with the actual histologic diagnosis. negative predictive value for the prediction of non-neoplastic polyp and concordance of surveillance intervals for diminutive polyps diagnosed optically with high confidence will be measured. in addition, the characteristics of the endoscopist affecting the performance of optical diagnosis were investigated.

Eligibility criteria:
inclusion criteria: 1. board-certified gastroenterologists 2. endoscopists who finished ex-vivo optical diagnosis training exclusion criteria: 1. inflammatory bowel disease 2. previous colon cancer history 3. previous colon op. history 4. melanosis coli
study to assess the safety of dupilumab (regn668/sar231893) administered concomitantly with topical corticosteroids (tcs) in patients with moderate-to-severe atopic dermatitis (ad)

Conditions: Atopic Dermatitis

Summary: the purpose of this study was to assess the safety of dupilumab administered concomitantly with topical corticosteroids (tcs) in patients with moderate-to-severe atopic dermatitis (ad).


Eligibility criteria:
inclusion criteria: 1. male and female patients aged 18 years or older 2. chronic ad that had been present for at least 2 years exclusion criteria: 1. prior treatment with dupilumab 2. hypersensitivity to corticosteroids or to any other ingredients contained by the tcs product used in the study 3. ad lesions located on face, flexural, and genital areas 4. certain treatments and medical procedures, undertaken within a particular time frame prior to the baseline visit, preclude eligibility for participation in the study 5. treatment with a live (attenuated) vaccine within 12 weeks before the baseline visit 6. treatment with an investigational drug within 8 weeks 7. known history of human immunodeficiency virus (hiv) infection 8. presence of certain laboratory abnormalities at the screening visit 9. history of certain opportunistic infections or certain clinical parasite infections 10. history of malignancy within 5 years before the baseline visit, with certain exceptions 11. pregnant or breast-feeding women 12. travel within 12 months of study start to areas endemic for parasitic infections, such as developing countries in africa and the tropical and subtropical regions of asia 13. history of alcohol or drug abuse within 2 years of the screening visit 14. any medical or psychiatric condition which, in the opinion of the investigator or the sponsor's medical monitor, would place the patient at risk, interfere with participation in the study, or interfere with the interpretation of study results